What do cited papers show on Selank peptide degradation pathways stability?
The supplied bibliographic set answers a naming question, not a stability question. Across these records Selank is identified as a peptide analogue of tuftsin, including PMID:36322304, PMID:31625062, PMID:24291245, PMID:24450168, and PMID:21609736. PMID:28745220 surveys tuftsin properties and analogues and locates the chemical family. PMID:21786679 is indexed to Selank and its fragments. PMID:16963804 and PMID:8704608 use the older label TP-7 for a tuftsin analogue. PMID:12154572 refers to Selank together with short peptides of Taftsin derivatives, and that title spelling should be preserved.
None of those records is a stability monograph. They do not state chromatographic purity, an assay value, a water determination, a counter-ion, a related-substances table, a forced-degradation result, or a time point at which purity was remeasured. Queries that joined Selank to degradation pathways and analytical characterisation still returned this experimental-biology literature. The conclusion to write into the file is negative: these PMIDs were checked for stability content and did not provide it.
That negative statement stops a later reader from treating a gene-expression time course as a chemical half-life. Temporary dynamics in the PMID:24291245 title refers to the timing of transcript measurements, not to loss of the heptapeptide. It also stops a fragment paper from being misread as a quantified impurity profile. The only positive statement the set will bear is narrow. In this literature Selank is a named tuftsin analogue, and shorter species have been discussed as distinct experimental materials. Any pathway sentence in this note is scaffold reasoning and still requires lot-level measurement. A citation placed beside a chromatogram does not assign a peak. The gap is recorded as a gap, not filled from a neighbouring peptide.
How is Selank identity defined before a stability result can be interpreted?
Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg. The conventional structural assignment for Selank is that tetrapeptide extended by Pro-Gly-Pro, giving Thr-Lys-Pro-Arg-Pro-Gly-Pro. The free-acid form then has elemental composition C33H57N11O9 and a calculated monoisotopic mass of 751.434 Da. Singly and doubly protonated calculated targets are m/z 752.442 and m/z 376.725. Those figures are laboratory identity targets. They are not measurements copied from the cited papers. The supplied records name an analogue relationship; they do not, in the fields available here, print a residue table or a mass window. Pathway language built on the wrong structure will name the wrong products, so identity confirmation is the first control.
Name concordance is separate. PMID:16963804 and PMID:8704608 index TP-7 as a tuftsin analogue, while PMID:12154572 indexes Selank with short peptides of Taftsin derivatives. Equating those labels because the titles look related is not an identity test. Spellings differ, including Taftsin and taftsin, and should be copied unchanged when the paper is cited. Historical labels may be noted on a lot only after sequence-ion coverage or intact mass links them to the material in hand. Until then, TP-7 is a neighbouring name, not a synonym proven by this bibliography.
Side chains set both detection and the pathway exclusions that follow. The conventional heptapeptide contains Thr, Lys, Pro, Arg, and Gly, with no Trp, Tyr, or Phe, so absorbance near 280 nm is a poor primary channel. Peptide-bond absorbance at shorter ultraviolet wavelength is the relevant chromatographic signal. Absence of Met and Cys, once identity is confirmed, removes methionine sulfoxide and disulfide chemistry from the expected list. A counter-ion adduct that shifts observed mass must be assigned, not called a degradant. Area-normalised purity, intact mass, and related substances are different attributes and must not be collapsed into one percentage.
How should Selank fragments in the literature be separated from degradant peaks?
PMID:21786679 is the clearest signal in this set for shorter species: its indexed title names Selank and its fragments. PMID:12154572 places Selank beside short peptides of Taftsin derivatives. They do not show that a stored lot produced those chains, which bond cleaved, what the relative retention time was, or what fraction of peak area they represented.
Four labels keep literature names and measured peaks apart. A specified related substance has a structure assigned for the method in use, ordinarily by intact mass and sequence ions that match a proposed cleavage. An unspecified related substance is a peak above the reporting threshold of that method, still without a structure. A literature fragment is a name from a paper, held in the nomenclature register until a peak is matched to it. A conformational peak has the parent mass and a different retention. Proline-rich sequences can separate cis and trans isomers without a covalent change, so scoring that class as degradation overstates chemical change.
Hydrolysis is the fragment hypothesis most closely tied to the scaffold. Cleavage of any of the six amide bonds yields two shorter peptides whose masses, after addition of water, sum to the parent. Residues 1-4, the tuftsin-like segment, and the C-terminal Pro-Gly-Pro segment are useful marker hypotheses because short tuftsin derivatives and Selank fragments already appear as separate objects in the literature. A peak may be called tuftsin-like only after mass and sequence ions agree with Thr-Lys-Pro-Arg. Retention time taken from another column or another peptide is not identification. Copying a fragment name from PMID:21786679 onto unmatched area would invent a pathway the paper did not measure.
Which Selank degradation pathways are sequence-plausible, and which are excluded?
Once a lot is confirmed as Thr-Lys-Pro-Arg-Pro-Gly-Pro, several common peptide pathways are structurally excluded. No methionine means a +16 Da sulfoxide is not expected from the authentic sequence. No cysteine means disulfide formation and scrambling do not apply. No asparagine or glutamine means deamidation, a +0.984 Da shift, is not a primary pathway unless a substitution has introduced one of those residues. An unexpected near-+1 Da species is then an identity or impurity finding, not ordinary Selank deamidation. No tryptophan lowers the priority of aromatic oxidation relative to a Trp-containing chain. These exclusions are structural reasoning. They are not measurements in PMID:28745220 or in the animal experiments.
What remains is backbone chemistry and stereochemistry. Hydrolysis can open any amide bond and produce the fragment pairs already described. Bond preference is not in the cited records and is not estimated here. Racemisation at residues with an abstractable alpha-proton can create diastereomers that reversed-phase chromatography may only partly resolve. A small early peak is not a racemate without a stereochemical test, and this bibliography does not contain one.
Three proline residues put cis-trans isomerism on the boundary between chromatography and chemistry. Isomerism can split the main peak without a mass change. For every extra peak the stability reading asks whether mass changed. Same mass favours a conformer until a covalent change is shown. Changed mass is tabulated as a related substance even if the structure is unspecified. Diketopiperazine is lower priority because position 2 is lysine, not proline, so the classic N-terminal X-Pro pattern is absent. It is not written here as the leading pathway.
Acid, base, oxidative, photolytic, and thermal stress are class names for challenging whether a method can see covalent change. They are not instructions. No medium, concentration, temperature, or duration is stated, because the supplied sources do not support any such figure.
What belongs in a Selank stability file when the literature gives no limits?
A research stability file can be complete without numerical limits copied from elsewhere. Completeness means traceable fields and explicit gaps. The identity block records the conventional sequence, the calculated monoisotopic mass of 751.434 Da, the observed mass, the charge state, and whether tandem-MS ions covered residues 1-4 and the C-terminal Pro-Gly-Pro segment. It states that the cited papers supplied analogue nomenclature, not the mass measurement. If the observed mass disagrees with 751.434 Da after adducts are considered, pathway language stops until identity is resolved.
The chromatographic block records method identity, why the detection wavelength was chosen, and the peak table obtained. Area-normalised purity is filed apart from content or counter-ion results. Relative retention time is reported only for the method that produced it. A reporting threshold is entered only if that method has one. It is not taken from a monograph these papers do not contain. Peaks below the threshold are not reported; they are not described as absent.
Mass balance puts main-peak area, specified related substances, unspecified related substances, and any assigned loss of signal in one place. Unexplained area stays unexplained. Only rows with a mass shift or sequence assignment are mapped to a hypothesis: hydrolysis fragment, unexpected substitution, conformer, or unidentified covalent species. For confirmed Thr-Lys-Pro-Arg-Pro-Gly-Pro, methionine oxidation, disulfide chemistry, and Asn/Gln deamidation are marked not sequence-expected, so a template from a Met-containing peptide is not pasted onto Selank. The file is not a human-use document, restates no endpoints from PMID:36322304 or PMID:31625062, and contains no workup steps. A missing number remains a blank with a reason.
How should experimental Selank papers be filed beside a stability record?
Experimental papers in this set have a bibliographic filing role only. PMID:36322304 and PMID:31625062 identify Selank as a tuftsin analogue in animal experiments. Their endpoints are not stability readouts and are not repeated here. PMID:24291245 uses a time base for gene expression, not for a purity retest. PMID:21609736 and PMID:24450168, in spleen and hippocampus, support only the historical use of the name. They do not support a storage interval or a degradant structure.
PMID:21786679 is filed twice: under fragment vocabulary, and under a warning that the paper is an expression experiment, not a related-substances assay. PMID:12154572 is filed under short-peptide nomenclature with the spelling Taftsin preserved. PMID:16963804 and PMID:8704608 stay under the TP-7 label unless lot-level sequence evidence creates a synonym line. PMID:17385425 is an older physiology paper; its title is not converted here into an analytical claim or into guidance for people. PMID:28745220 anchors the tuftsin family and is not a lot-release document.
Three registers prevent the query from being answered with the wrong evidence. Register A holds names, family, and fragment vocabulary, with PMID, title, journal, and year copied unchanged. Register B holds lot measurement: mass, chromatogram, related substances, and any stress comparison performed on that lot. Register C stays empty when no measurement exists. Mixing A into B is the error this search invites. An empty register C is preferable to plausible chemistry written as if it had been observed. Research-use-only framing sits in the header of each register so the note cannot be stripped of its boundary and read as guidance for people.
Frequently asked questions
Do the cited papers report a Selank half-life or purity limit?
No. The cited records identify Selank as a tuftsin analogue and, in PMID:21786679, name fragments in an expression experiment. They do not report a half-life, a chromatographic purity, a related-substances limit, or a forced-degradation peak. A blank field is the accurate transcription. Estimating a figure from unrelated peptide practice would falsify the stability file.
Is a literature fragment the same as a degradant in a tested lot?
No. PMID:21786679 and PMID:12154572 show that shorter species have been named beside Selank in experimental writing. A degradant is a related substance measured in the lot and assigned, where possible, by mass and sequence ions. Until that match exists, the literature name stays in the nomenclature register and any unmatched peak stays unspecified.
Why is methionine oxidation not the leading pathway for confirmed Selank?
The conventional heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro contains no methionine, cysteine, asparagine, or glutamine. Methionine sulfoxide, disulfide chemistry, and Asn/Gln deamidation are therefore not sequence-expected once identity is confirmed. An unexpected mass shift of that type would prompt an identity or impurity investigation rather than a standard pathway label. This exclusion is structural reasoning, not a result from the cited animal studies.
Can an extra chromatographic peak be a proline conformer rather than degradation?
It can. A sequence with three proline residues can show cis-trans isomerism that changes retention without changing mass. A stability reading should compare mass before it assigns a pathway. Same-mass extra peaks are flagged as conformational, or otherwise non-covalent, until a covalent change is shown. Changed-mass peaks are tabulated as related substances even when the structure is still unspecified. The cited papers do not resolve that ambiguity for any lot.
What should a reviewer do if a stability number is missing?
Leave the field blank and record the reason: the supplied peer-reviewed records do not contain it, and no lot measurement has been entered. Do not copy a limit from another peptide, and do not convert a gene-expression time course into a chemical half-life. Temporary dynamics in PMID:24291245 refers to transcript timing. Research documentation is more reliable with an explicit gap than with a borrowed figure.
Does this note set out workup steps or human-use guidance?
No. The note is research-use-only analytical documentation. It does not describe workup, storage practice, or use in people or animals. Papers such as PMID:36322304 and PMID:31625062 remain experimental records. Their endpoints are not restated and are not translated into practice. The only procedural content is how to file identity literature separately from stability claims that have not been measured.
References
- PMID:36322304 — Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bull Exp Biol Med — 2022
- PMID:31625062 — Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats — Bull Exp Biol Med — 2019
- PMID:28745220 — Tuftsin - Properties and Analogs — Curr Med Chem — 2017
- PMID:24291245 — The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action — Mol Immunol — 2014
- PMID:21609736 — Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank — Regul Pept — 2011
- PMID:24450168 — [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank] — Zh Vyssh Nerv Deiat Im I P Pavlova — 2013
- PMID:16963804 — Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight — Pharmacol Rep — 2006
- PMID:21786679 — [Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments] — Genetika — 2011
- PMID:17385425 — [Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia] — Ross Fiziol Zh Im I M Sechenova — 2006
- PMID:12154572 — [Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress] — Ross Fiziol Zh Im I M Sechenova — 2002
- PMID:8704608 — [The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity] — Eksp Klin Farmakol — 1995
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
